Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
Webcast events can be accessed live, and replays will be archived for 90 days and available through the Investors page on the Perspective website at . SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.
2024年11月27日，西雅圖（全球新聞資訊社）- Perspective Therapeutics, Inc.（"透視"或"公司"）(紐交所美國: CATX)，一家開拓癌症全身治療領先愛文思控股的放射製藥公司，今天宣佈其高級領導團隊成員將參加並與投資者在以下即將舉行的投資者會議上進行一對一會議。
36th Annual Piper Healthcare Conference
Date: December 3, 2024
Location: New York, NY
Format: Fireside Chat
Time: 10:00-10:25 AM ET
第36屆Piper醫療保健大會
日期：2024年12月3日
地點：紐約，紐約州
格式：爐邊聊天
時間：東部時間上午10:00-10:25
7th Annual Evercore HealthCONx
Date: December 5, 2024
Location: Coral Gables, FL
Format: Fireside Chat
Time: 10:50-11:10 AM ET
第7屆Evercore HealthCONx大會
日期：2024年12月5日
地點：佛羅里達科勒爾蓋布爾斯
格式：爐邊聊天
時間：上午10:50-11:10 ET
Webcast events can be accessed live, and replays will be archived for 90 days and available through the Investors page on the Perspective website at .
網絡研討會可現場觀看，並且重播將存檔90天，並通過Perspective網站的投資者頁面進行回放。
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
關於 Perspective Therapeutics公司
Perspective Therapeutics Inc.是一家放射性製藥公司，致力於開創全身各部位癌症治療的先進技術。該公司擁有專有技術，利用α放射性同位素212Pb通過專門定位的肽子將強大的輻射能量精確傳遞到癌細胞。該公司還在開發互補成像診斷方法，這些成像診斷方法包括與相同定位肽相結合，這提供了個性化治療的機會，並優化患者的治療效果。這種「診治一體化」方法能夠在看到具體腫瘤並針對性治療的同時，促進治療效果的提高、毒性反應的最小化。
The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.
該公司的黑色素瘤（VMT01）和神經內分泌腫瘤（VMt-α-NET）項目已經進入了幾個領先的學術機構的轉移性黑色素瘤和神經內分泌腫瘤的第1/2a期成像和治療試驗。該公司還開發了一種專有的212Pb發生器，以確保臨床試驗和商業運營的關鍵同位素。
For more information, please visit the Company's website at .
欲了解更多信息，請訪問該公司的網站。
CONTACT: Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com
聯繫人：媒體和投資者關係聯繫人：
Perspective Therapeutics IR：
Annie J. Cheng, 愛文思控股
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com
